GR-389988   Click here for help

GtoPdb Ligand ID: 10257

Synonyms: Ex. 3-15 [US9174986B2] | GR389988 | GZ389988 | GZ389988A
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: GR-389988 (a.k.a. GZ389988) is a neurotrophic receptor tyrosine kinase/Trk inhibitor that was developed by Genzyme. It blocks nerve growth factor (NGF)/Trk pathway activation. The chemical structure is claimed in Genzyme's patent US9174986B2 for utility in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and especially for the management of osteoarthritis and osteoarthritis pain. GR-389988 also inhibits c-FMS, the cellular receptor for colony stimulating factor-1 (CSF-1).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 8
Topological polar surface area 102.24
Molecular weight 470.21
XLogP 4.1
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COc1cc(ccc1OCc1ccc(cc1)OC)Cn1c(N)nc2c1ncc(c2)c1cnn(c1)C
Isomeric SMILES COc1cc(ccc1OCc1ccc(cc1)OC)Cn1c(N)nc2c1ncc(c2)c1cnn(c1)C
InChI InChI=1S/C26H26N6O3/c1-31-15-20(13-29-31)19-11-22-25(28-12-19)32(26(27)30-22)14-18-6-9-23(24(10-18)34-3)35-16-17-4-7-21(33-2)8-5-17/h4-13,15H,14,16H2,1-3H3,(H2,27,30)
InChI Key HVRWZFQFSQUILC-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
GZ389988 has completed Phase 2 proof-of-concept evaluation in patients with knee osteoarthritis (see NCT02845271), for which results were published in 2019 [2]. As of August 2021, there were no active studies of GZ389988 listed on ClinicalTrials.gov.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02845271 Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee Phase 2 Interventional Sanofi In this study a single intra-articular injection of GZ389988A reduced pain and improved function compared to placebo, in participants with painful knee osteoarthritis, with an acceptable safety profile. 2